Shaperon is an innovative biotech company specializing in the development of novel immunology-based therapies targeting immune-mediated inflammatory disorders. With a strong focus on unmet medical needs, Shaperon is pioneering a pipeline that includes cutting-edge treatments such as NuGel®, NuCerin®, and Oral Inflammasome Inhibitors like Papiliximab® and Saviximab®. The company leverages advanced technologies, including their proprietary AI-driven drug discovery platform, AIDEN, to optimize candidate compounds and streamline the research process.

One of Shaperon's key innovations is the Nanobody, a unique, single-domain antibody derived from camelids that offers enhanced stability and tissue penetration compared to traditional antibodies. This platform sets the stage for the development of multiple biotherapeutics aimed at tackling chronic diseases like cancer and obesity. Shaperon is committed to revolutionizing immunotherapy by providing effective treatments for conditions where current therapies fall short, establishing itself as a leader in the field of immunology.